DelveInsight’s “Trigeminal Neuralgia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Trigeminal Neuralgia, historical and forecasted epidemiology as well as the Trigeminal Neuralgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Trigeminal Neuralgia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Trigeminal Neuralgia Market Forecast
Some of the key facts of the Trigeminal Neuralgia Market Report:
The Trigeminal Neuralgia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In April 2025, Noema Pharma AG announced a clinical study aimed at assessing the effectiveness and safety of basimglurant (NOE-101) at doses ranging from 1.5 mg to 3.5 mg in adults with trigeminal neuralgia (TN). Basimglurant is a strong inhibitor of metabotropic glutamate receptor 5 (mGluR5), which plays a key role in various functions of the central and peripheral nervous systems. Blocking mGluR5 has demonstrated promising potential for relieving pain linked to conditions like Trigeminal Neuralgia.
In March 2025, NeuroOne Medical Technologies accelerated its timeline for submitting a 510(k) application to the U.S. Food and Drug Administration (FDA) for its trigeminal nerve ablation technology, now scheduled for May 2025. This innovation is based on the company’s OneRF platform.
In December 2024, Noema Pharma, a clinical-stage biotechnology company focused on treating serious central nervous system (CNS) disorders, announced the completion of a Series B extension funding round. The round included an investment from EQT Life Sciences, raising the total capital secured to CHF 130 million (approximately USD 147 million). The funds will advance Noema Pharma’s ongoing four Phase 2 clinical trials, with key data expected in 2025. These trials include continued development of basimglurant (NOE-101), an mGluR5 negative allosteric modulator being tested for trigeminal neuralgia-related severe pain and tuberous sclerosis complex (TSC)-related seizures; gemlapodect (NOE-105), a PDE10a inhibitor in a Phase 2b study for Tourette syndrome and also being developed for childhood-onset fluency disorder (COFD/stuttering); and NOE-115, a monoamine modulator in Phase 2 for treating vasomotor and other menopausal symptoms.
In August 2024, Noema Pharma AG, a clinical-stage biotech company developing innovative therapies for severe neuroscience-related disorders, announced the completion of enrollment for the GALENE Phase 2B trial. This double-blind, placebo-controlled study is assessing the efficacy of NOE-101 in managing seizures associated with tuberous sclerosis complex (TSC). NOE-101, also known as basimglurant, is a potent inhibitor of metabotropic glutamate receptor 5 (mGluR5) and is also being clinically investigated for the treatment of trigeminal neuralgia.
The National Organisation for Rare Disorders (NORD) reports that women are slightly more likely than men to experience trigeminal neuralgia. Although the actual incidence is unknown, the United States sees between 10,000 and 15,000 new cases annually
According to a study by Lambru et al. (2020), the yearly incidence of TN is projected to be 4-29 per 100 000 person-years, while the lifetime prevalence is estimated to be 0.16%-0.3%. Women are more likely than men to have it. With a mean age of onset of 53–57 years and a range of 24-93 years in adult series, the incidence rises with age
Key Trigeminal Neuralgia Companies: Noema Pharma AG, Biohaven Pharmaceuticals, Biogen, Eli Lilly and Company, Novartis, and others
Key Trigeminal Neuralgia Therapies: Basimglurant, Rimegepant, CNV1014802, Galcanezumab, COA566, and others
The Trigeminal Neuralgia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Trigeminal Neuralgia pipeline products will significantly revolutionize the Trigeminal Neuralgia market dynamics.
Trigeminal Neuralgia Overview
The trigeminal nerve, or fifth cranial nerve, is one of the most extensively dispersed nerves in the head and is affected by the chronic pain syndrome known as trigeminal neuralgia (TN), sometimes known as tic douloureux. It falls within the category of neuropathic pain, which can be divided into two categories: primary (idiopathic) and secondary.
Get a Free sample for the Trigeminal Neuralgia Market Report:
https://www.delveinsight.com/report-store/trigeminal-neuralgia-market
Trigeminal Neuralgia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Trigeminal Neuralgia Epidemiology Segmentation:
The Trigeminal Neuralgia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Total Prevalence of Trigeminal Neuralgia
Prevalent Cases of Trigeminal Neuralgia by severity
Gender-specific Prevalence of Trigeminal Neuralgia
Diagnosed Cases of Episodic and Chronic Trigeminal Neuralgia
Download the report to understand which factors are driving Trigeminal Neuralgia epidemiology trends @ Trigeminal Neuralgia Epidemiology Forecast
Trigeminal Neuralgia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Trigeminal Neuralgia market or expected to get launched during the study period. The analysis covers Trigeminal Neuralgia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Trigeminal Neuralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Trigeminal Neuralgia Therapies and Key Companies
Basimglurant: Noema Pharma AG
Rimegepant: Biohaven Pharmaceuticals
CNV1014802: Biogen
Galcanezumab: Eli Lilly and Company
COA566: Novartis
Discover more about therapies set to grab major Trigeminal Neuralgia market share @ Trigeminal Neuralgia Treatment Market
Scope of the Trigeminal Neuralgia Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Trigeminal Neuralgia Therapeutic Assessment: Trigeminal Neuralgia current marketed and Trigeminal Neuralgia emerging therapies
Trigeminal Neuralgia Market Dynamics: Trigeminal Neuralgia market drivers and Trigeminal Neuralgia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Trigeminal Neuralgia Unmet Needs, KOL’s views, Analyst’s views, Trigeminal Neuralgia Market Access and Reimbursement
To know more about Trigeminal Neuralgia companies working in the treatment market, visit @ Trigeminal Neuralgia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Trigeminal Neuralgia Market Report Introduction
2. Executive Summary for Trigeminal Neuralgia
3. SWOT analysis of Trigeminal Neuralgia
4. Trigeminal Neuralgia Patient Share (%) Overview at a Glance
5. Trigeminal Neuralgia Market Overview at a Glance
6. Trigeminal Neuralgia Disease Background and Overview
7. Trigeminal Neuralgia Epidemiology and Patient Population
8. Country-Specific Patient Population of Trigeminal Neuralgia
9. Trigeminal Neuralgia Current Treatment and Medical Practices
10. Trigeminal Neuralgia Unmet Needs
11. Trigeminal Neuralgia Emerging Therapies
12. Trigeminal Neuralgia Market Outlook
13. Country-Wise Trigeminal Neuralgia Market Analysis (2019–2032)
14. Trigeminal Neuralgia Market Access and Reimbursement of Therapies
15. Trigeminal Neuralgia Market Drivers
16. Trigeminal Neuralgia Market Barriers
17. Trigeminal Neuralgia Appendix
18. Trigeminal Neuralgia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
